Drug Trial Radar · NCT05867251
Study of AVZO-021 in Patients With Advanced Solid Tumors
Last checked: Nov 19, 2026Latest source record: Sep 28, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Recruiting
Enrollment
430
Planned (sponsor's estimate)
Start
Aug 30, 2023
Primary completion
Jan 31, 2028
Study completion Jan 31, 2030
Sponsor
- Lead sponsor
- Avenzo Therapeutics, Inc.Industry
- Sponsor type
- Industry
- First posted
- May 19, 2023
Design
- Study type
- Interventional
- Phase
- Phase 1 / Phase 2
- Allocation
- Non randomized
- Model
- Sequential
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This study, the first clinical trial of AVZO-021, aims to determine the safety, tolerability, pharmacokinetics, pharmacodynamics, maximum tolerated dose, and anti-tumor effects of AVZO-021 in patients with advanced solid tumors. AVZO-021 is an oral medication that inhibits cyclin-dependent kinase 2 (CDK 2).
Conditions
- Advanced Solid Tumor
- HR+/HER2- Breast Cancer
- HR+, HER2-, Advanced Breast Cancer
- CCNE1 Amplification
- Epithelial Ovarian Cancer
- Primary Peritoneal Cancer
- Fallopian Tube Cancer
- Endometrial Cancer
- TNBC - Triple-Negative Breast Cancer
Interventions
AVZO-021Drug
AVZO-021 is a selective and potent oral inhibitor of CDK2 being developed for the treatment of patients with advanced solid tumors with CDK2 dependency (1A), CCNE1 amplified solid tumors (2A), HR+/HER2- BC (1B1-1B5, 2B1-2B5) and CCNE1 amplified EOC (1C, 2C)
PalbociclibDrug
Antineoplastic agent, cyclin-dependent kinase 4/6 inhibitor
FulvestrantDrug
Antineoplastic agent, estrogen receptor antagonist
LetrozoleDrug
Antineoplastic agent, aromatase inhibitor
RibociclibDrug
Antineoplastic CDK4/6 inhibitor
AbemaciclibDrug
Antineoplastic CDK4/6 inhibitor
CarboplatinDrug
Alkylating agent
Sacituzumab Govitecan-hziyDrug
Trop-2 antibody and topoisomerase inhibitor
Primary outcomes
What the sponsor says the trial is designed to measure.
- Occurrence of Dose Limiting Toxicities (DLTs) during the first cycle (Phase 1)Time frame: 28 Days
- Number of Participants with Treatment Emergent Adverse Events (TEAEs) and lab abnormalities (Phase 1)Time frame: Approximately 22 months
- Determination of Recommended Phase 2 Dose (RP2D) (Phase 1)Time frame: Approximately 16 months
- Objective Response Rate (ORR) (Phase 2)Time frame: Approximately 52 months
- Progression Free Survival (PFS) (Phase 2)Time frame: Approximately 52 months
- Overall Survival (OS) (Phase 2)Time frame: Approximately 76 months
- Duration of response (DOR) (Phase 2)Time frame: Approximately 52 months
Locations
13 sites in 2 countries. Site status is shown where the registry gives one.
Avenzo Therapeutics Recruiting Site
New Haven, Connecticut · Recruiting
Avenzo Therapeutics Recruiting Site
Sarasota, Florida · Recruiting
Avenzo Therapeutics Recruiting Site
Tampa, Florida · Recruiting
Avenzo Therapeutics Recruiting Site
Mineola, New York · Recruiting
Avenzo Therapeutics Recruiting Site
New York, New York · Recruiting
Avenzo Therapeutics Recruiting Site
Cleveland, Ohio · Recruiting
Avenzo Therapeutics Recruiting Site
Oklahoma City, Oklahoma · Recruiting
Avenzo Therapeutics Recruiting Site
Portland, Oregon · Recruiting
Avenzo Therapeutics Recruiting Site
Philadelphia, Pennsylvania · Recruiting
Avenzo Therapeutics Recruiting Site
Dallas, Texas · Recruiting
Avenzo Therapeutics Recruiting Site
Fairfax, Virginia · Recruiting
Avenzo Therapeutics Recruiting Site
Macquarie University, New South Wales, Australia · Recruiting
Avenzo Therapeutics Recruiting Site
Wollongong, New South Wales, Australia · Recruiting
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.